March 2012
Volume 53, Issue 14
ARVO Annual Meeting Abstract  |   March 2012
Use of a Short hPDE6b Promoter For Rod Gene Transfer in a Model of Severe Retinal Dystrophy, the Rd10 Mouse
Author Affiliations & Notes
  • Yvan Arsenijevic
    Unit of Gene Therapy & Stem Cell Biology, Jules-Gonin Eye Hospital, Univ Lausanne, Lausanne, Switzerland
  • Corinne Kostic
    Gene Therapy & Stem Cell Biol, Jules-Gonin Eye Hosp, Univ Lausanne, Lausanne, Switzerland
  • Alberto Auricchio
    Telethon Institute of Genetics and Medicine and Dep. of Pediatrics, "Federico II" University, Napoli, Italy
  • JongEun Ihm
    UGTSCB, Hospital de l'Ophthal, Jule-Gonins, Lausanne, Switzerland
  • Footnotes
    Commercial Relationships  Yvan Arsenijevic, None; Corinne Kostic, None; Alberto Auricchio, None; JongEun Ihm, None
  • Footnotes
    Support  FP7AAVEYE HEALTH-2007-B-223445
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 1925. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Yvan Arsenijevic, Corinne Kostic, Alberto Auricchio, JongEun Ihm; Use of a Short hPDE6b Promoter For Rod Gene Transfer in a Model of Severe Retinal Dystrophy, the Rd10 Mouse. Invest. Ophthalmol. Vis. Sci. 2012;53(14):1925.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : Gene therapy of severe retinal dystrophies directly affecting photoreceptor is still a challenge in terms of clinical application. One of the main hurdles is to generate high transgene expression specifically in rods or cones. In the present study, we are investigating the possibility to drive hPDE6b expression in the Rd10 mouse retina using a specific sequence of the human PDE6b promoter.

Methods: : Two 5’ flanking fragments of the human PDE6b gene: (-93 to +53 (146 bp) and -297 to +53 (350 bp, see Di Polo and Farber, 1995) were cloned in different plasmids in order to check their expression in vitro and in vivo. These elements drove the activity of either luciferase (pGL3 plasmids) or EGFP (AAV2/8 backbone). Then, an AAV2/8 vector carrying the PDE6b cDNA was tested with subretinal injections at P9 in the Rd10 eyes. Eye fundus, OCT, ERG recordings and histological investigations were performed to assess the efficacy of the gene transfer.

Results: : The short PDE6b promoter containing 146bp (-93 to +53) showed the highest activity in the Y-79 cells, as described previously (Di Polo and Farber, 1995). Subretinal administrations of AAV2/8-PDE6bpromoter-EGFP allowed a rapid expression specifically in rods and not in cones. The expression is faster than a vector containing the CMV promoter. The AAV2/8-PDE6bpromoter-PDE6b and the control vector were injected at P9 in the Rd10 mouse retina and investigated 5 weeks post-injection. Out of 14 eyes, 6 presented an increased rod sensitivity of about 300 fold, and increased a- and b-wave responses in ERG recordings. Flicker stimulations revealed that cones are also functional. OCT images and histological analyses revealed an increased ONL size in the injected area. The retina treated with the therapeutic vector presented 4-6 rows of photoreceptors with outersegments containing PDE6b. In the control eyes, only 2-4 rows of photoreceptors with almost no OS were observed .

Conclusions: : The 146 bp promoter sequence (-93 to + 53) is the shortest regulatory element described to date which allows to obtain efficient rod-specific expression in the context of somatic gene transfer. This first result is of great interest for AAV vector design in general allowing more space for the accommodation of transgenes of interest and good expression in rods. Moreover we showed the proof of principle of the efficacy of AAV2/8-PDE6bp-PDE6b vector in the Rd10 mouse model of severe photoreceptor degeneration without using neither AAV mutated capsids, nor self-complementary vectors.

Keywords: retinal degenerations: hereditary • gene transfer/gene therapy • photoreceptors 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.